Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576
Trial details
- Registry ID
- NCT03588026
- Drugs studied
- Standard of care (SOC), rVA576
TrialRedline tracks 6 clinical trials sponsored by AKARI Therapeutics: 3 Phase 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576NCT03588026 | Standard of care (SOC), rVA576 | Completed | 2020-09-03Actual |
| Nomacopan (rVA576) in Transplant Associated Thrombotic MicroangiopathyNCT04784455 | nomacopan (rVA576) | Terminated | 2024-05-15Actual |
| rVA576 (Coversin) Long Term Safety and Efficacy Surveillance StudyNCT03829449 | rVA576 | Terminated | 2020-08-29Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| rVA576 in Adult Mild to Moderate Bullous Pemphigoid SubjectsNCT04035733 | rVA576 | Completed | 2020-03-12Actual |
| Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 PolymorphismsNCT03427060 | Coversin | Completed | 2018-11-15Actual |
| Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)NCT02591862 | Coversin | Completed | 2018-03-20Actual |
Names as written in the registry records.